Obsidian Therapeutics, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
This is a routine quarterly report (10-Q) for Obsidian Therapeutics, Inc. for the period ending June 30, 2026, filed on August 14, 2026. The filing document itself contains no disclosed material transactions, counterparties, dollar amounts, share counts, or business developments—only standard SEC form headers, exhibits (certifications and attestations), and XBRL data formatting. No substantive financial or operational details are extractable from the metadata provided.
Why this rating
Routine quarterly filing submission. No material events, transactions, or guidance changes disclosed in available text. Standard administrative disclosure.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.